Compound News and Research

RSS

Pulmatrix raises $30.2 million through Series B financing

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced that it has secured $30.2 million in Series B financing. ARCH Venture Partners and Novartis Bioventures Fund co-led the round with participation from existing investors Polaris Venture Partners and 5AM Ventures.

2 Nov 2009

Requests to compound liquid Tamiflu have steadily increased over the past couple of weeks

There has been a lot of information about the importance of taking preventative measures against H1N1, primarily through vaccination. But what if a person has already contracted H1N1? What if that person is a young child?

31 Oct 2009

Eisai reports global Phase III study results of eribulin mesylate

Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer.

30 Oct 2009

ARYx Therapeutics to complete an out-licensing agreement for clinical development and commercialization of budiodarone

ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that it has implemented a staffing plan to operate the company that anticipates licensing its lead development programs and resuming development of earlier stage product candidates.

30 Oct 2009

Researchers report preclinical results of a novel PET biomarker designed to detect malignant breast tumors

Researchers at Thomas Jefferson University in Philadelphia, PA, supported in part by NuView Life Sciences, have published an article in the Journal of Nuclear Medicine reporting preclinical results of a novel PET biomarker designed to selectively detect malignant breast tumors.

30 Oct 2009

Study: HSP inhibitor could stop tumor formation and extend survival

Like yoga for office drones, cells do have coping strategies for stress. Heat, lack of nutrients, oxygen radicals - all can wreak havoc on the delicate internal components of a cell, potentially damaging it beyond repair. Proteins called HSPs (heat shock proteins) allow cells to survive stress-induced damage. Scientists have long studied how HSPs work in order to harness their therapeutic potential.

30 Oct 2009

Fiscal 2009 results announced by Helix BioPharma

Helix BioPharma Corp. today announced financial results for the year ended July 31, 2009.

30 Oct 2009

2009 Schering-Plough Excellence Award for WuXi PharmaTech

WuXi PharmaTech (Cayman) Inc., a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company, with operations in China and the United States, today announced that it had received the 2009 Excellence Award from Schering-Plough.

30 Oct 2009

Online resource to illustrate genetic networks in common autoimmune diseases published

Currently, 5-8% of the U.S. population is afflicted with an autoimmune disease (www.niaid.nih.gov). Many of these are chronic and require life-long care. Moreover, different autoimmune diseases aggregate within a single family, suggesting they are caused by disruptions in common biological pathways.

30 Oct 2009

Unaudited consolidated financial results for the third-quarter reported by AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2009.

29 Oct 2009

Ipsen announces sales highlights for the first nine months of 2009

Ipsen reported its sales for the third quarter and first nine months of 2009.

29 Oct 2009

Report on marketing the bio-pharmaceutical products released

The bio-pharmaceutical marketplace - and the Oncology therapeutic area in particular - continues to evolve as new medicines and technologies create valuable market opportunities. It's in this competitive and challenging environment that organizations with new Oncology products are scrutinizing their strategies and tactics to support market education.

29 Oct 2009

Ergoplex, an anti-inflammatory product, receives good response in direct mail test

OXIS INTERNATIONAL, INC. (Pink Sheets: OXIS, Paris: OXI) announced today that Ergoplex™, its commercial anti-inflammatory product using its patented compound, Ergothioneine, a powerful antioxidant, has shown very good acceptance in a recent direct mail test.

29 Oct 2009

Cempra Pharmaceuticals to present CEM-102 data at the Infectious Diseases Society of America meeting

Cempra Pharmaceuticals today announced data presentations of its lead antibiotic candidate, CEM-102 (fusidic acid), at the Infectious Diseases Society of America, 47th Annual Meeting, Oct. 29 to Nov. 1, 2009, in Philadelphia.

29 Oct 2009

Positive top-line results from Phase IIb clinical trial of cariprazine announced

Forest Laboratories, Inc. and Gedeon Richter Plc today announced positive top-line results from a Phase IIb clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of acute exacerbation of schizophrenia.

29 Oct 2009

NIEHS supports research to study the potential effects of BPA on human health

Researchers studying the health effects of the chemical bisphenol A (BPA) gathered in North Carolina to launch an integrated research initiative to produce data that will allow for a comprehensive assessment of its possible human health effects.

29 Oct 2009

Cempra Pharmaceuticals stages a presentation on CEM-101

Cempra Pharmaceuticals today announced a presentation on its novel fluoroketolide antibiotic, CEM-101, at the Infectious Diseases Society of America, 47th Annual Meeting, October 29 to November 1, 2009, in Philadelphia.

29 Oct 2009

Roche discloses the results of first Phase III clinical study using Taspoglutide

Ipsen (Paris:IPN), an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of a first phase III clinical study using Taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s Research.

29 Oct 2009

New study demonstrates that stem cell therapy may help prevent acute lung injury

Researchers at the University of Illinois at Chicago College of Medicine have shown that adult stem cells from bone marrow can prevent acute lung injury in a mouse model of the disease.

29 Oct 2009

NIH awards DiscoveryBioMed grant to develop therapies for cystic fibrosis

DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a Phase 1 Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH). The $308,000 grant will be used to advance certain small molecule drug discovery programs designed to correct the genetic mutation most common to cystic fibrosis (CF).

28 Oct 2009

Compound News and Research

Pulmatrix raises $30.2 million through Series B financing

Requests to compound liquid Tamiflu have steadily increased over the past couple of weeks

Eisai reports global Phase III study results of eribulin mesylate

ARYx Therapeutics to complete an out-licensing agreement for clinical development and commercialization of budiodarone

Researchers report preclinical results of a novel PET biomarker designed to detect malignant breast tumors

Study: HSP inhibitor could stop tumor formation and extend survival

Fiscal 2009 results announced by Helix BioPharma

2009 Schering-Plough Excellence Award for WuXi PharmaTech

Online resource to illustrate genetic networks in common autoimmune diseases published

Unaudited consolidated financial results for the third-quarter reported by AMAG Pharmaceuticals

Ipsen announces sales highlights for the first nine months of 2009

Report on marketing the bio-pharmaceutical products released

Ergoplex, an anti-inflammatory product, receives good response in direct mail test

Cempra Pharmaceuticals to present CEM-102 data at the Infectious Diseases Society of America meeting

Positive top-line results from Phase IIb clinical trial of cariprazine announced

NIEHS supports research to study the potential effects of BPA on human health

Cempra Pharmaceuticals stages a presentation on CEM-101

Roche discloses the results of first Phase III clinical study using Taspoglutide

New study demonstrates that stem cell therapy may help prevent acute lung injury

NIH awards DiscoveryBioMed grant to develop therapies for cystic fibrosis

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News